Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Renal failure; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Registrational
- Acronyms REMODEL
- Sponsors Novo Nordisk
- 25 May 2024 This trial has been completed in Poland according to European Clinical Trials Database record.
- 18 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2023 Planned End Date changed from 17 Jul 2024 to 18 Nov 2024.